New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
September 27, 2013
11:55 EDTHALO, RHHBYHalozyme volatility at 16-month low after receiving milestone payment from Roche
Halozyme (HALO) overall option implied volatility of 70 is below its 26-week average of 88 according to Track Data, suggesting decreasing a day after receiving a $10M milestone payment from Roche (RHHBY).
News For HALO;RHHBY From The Last 14 Days
Check below for free stories on HALO;RHHBY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 23, 2014
09:08 EDTRHHBYUltragenyx appoints Sunil Agarwal, M.D. as Chief Medical Officer
Subscribe for More Information
July 22, 2014
09:04 EDTHALOHalozyme resumes enrollment and dosing of patients for PEGPH20 Phase 2 trial
Halozyme Therapeutics announced that it has resumed enrollment and dosing of patients in its ongoing Phase 2 trial evaluating PEGPH20 in patients with pancreatic cancer under the revised clinical protocol agreed to with the FDA in June. PEGPH20 is an investigational PEGylated form of Halozyme's proprietary recombinant human hyaluronidase under development for the systemic treatment of tumors that accumulate hyaluronan.
05:21 EDTRHHBYRoche announces Genentech Avastin granted priority review by FDA
Subscribe for More Information
July 21, 2014
07:11 EDTRHHBYInternational Society of DNA Vaccines to hold a conference
Subscribe for More Information
06:43 EDTRHHBYGrowing market for hepatitis-C treatment prompts legal scramble, WSJ says
Subscribe for More Information
July 20, 2014
15:42 EDTRHHBYRoche not looking for big acquisitions, Reuters says
Subscribe for More Information
July 17, 2014
17:42 EDTRHHBYCepheid says Roche patent suit will not have material adverse impact on results
Subscribe for More Information
July 16, 2014
11:23 EDTRHHBYRoche Alzheimer drug shows mixed results in trial, NYT says
Subscribe for More Information
06:26 EDTRHHBYBristol-Myers lung cancer trials being underestimated, says Citigroup
After building a statistical model of Bristol-Myers' two critical registration trials for Opdivo in lung cancer, Citigroup believes the market is "materially" underestimating both Phase III trials. Citi says potential Opdivo FDA approval in 2015 in lung cancer would give Bristol-Myers an up to two year lead time versus Merck (MRK) and Roche (RHHBY). The firm estimates 2023 Opdivo revenue at $7B and reiterates a Buy rating on Bristol with a $60 price target.
July 15, 2014
05:37 EDTRHHBYGenentech Avastin granted priority review by FDA
Subscribe for More Information
July 14, 2014
11:20 EDTRHHBYExelixis seen as potential target for Roche, TheStreet says
Subscribe for More Information
July 11, 2014
10:00 EDTHALOOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Altria Group (MO) initiated with an Outperform at Cowen... Berkshire Hills Bancorp (BHLB) initiated with a Hold at Jefferies... CGI Group (GIB) initiated with an Outperform at Credit Suisse... Halozyme (HALO) initiated with an Overweight at JPMorgan... Lorillard (LO) initiated with an Underperform at Cowen... MacroGenics (MGNX) initiated with an Outperform at Oppenheimer... Philip Morris (PM) initiated with a Market Perform at Cowen... Prothena (PRTA) initiated with an Outperform at Oppenheimer... Reynolds American (RAI) initiated with a Market Perform at Cowen... Seventy Seven Energy (SSE) initiated with a Buy at Wunderlich... SouFun (SFUN) initiated with a Neutral at Macquarie... Sprouts Farmers Markets (SFM) initiated with a Neutral at Longbow... Sterling Bancorp (STL) initiated with a Buy at Jefferies... Xencor (XNCR) initiated with an Outperform at Oppenheimer... YPF (YPF) initiated with a Neutral at JPMorgan... iGATE (IGTE) initiated with an Outperform at William Blair.
05:45 EDTHALOHalozyme initiated with an Overweight at JPMorgan
Subscribe for More Information
July 10, 2014
10:02 EDTRHHBYRoche unit, Merck KGaA to develop companion test for cancer treatment
Ventana Medical Systems, a member of the Roche Group (RHHBY), announced it has entered into an agreement with Merck KGaA (MKGAY), which operates as EMD Serono in the United States and Canada, to collaborate with Merck KGaA's biopharmaceutical division on the development and commercialization of a companion diagnostic for an undisclosed target using Ventana's proprietary diagnostic assays.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use